Vol. 2, Issue 10 (2013)

Author(s):
Iryna Savelikhina; Olena Deltsova; Vasyl Pertsovych; Sergiy Gerashchenko; Oleksandra Marchuk; Mykola Ostrovskyy

Abstract:
Chronic obstructive pulmonary disease (COPD) is a leading cause of mortality and morbidity both in developed and developing countries that is mainly characterized by progressive and not fully reversible airflow limitation. Roflumilast is a first-in-class oral once-daily phosphodiesterase type-4 inhibitor licensed for the treatment of COPD. Remodeling of respiratory tracts is a pathologic process observed at chronic inflammatory and obstructive diseases of respiratory tracts, and it is prescribed on the background of a COPD maintance treatment. For 9 people with severe COPD before treatment and after 30 and 180 days treatment with roflumilast were performed biopsies of the mucous membrane of the bronchi. Verification of the diagnosis and its formulation confirmed with the orders of Ministry of Health of Ukraine â„– 128 from 19.03.2007. "On approval of clinical protocols of medical care in the specialty pulmonology".